Resiliva 80 mg Tablet (Resmetirom)| Global Acces Named Patient Guide to Generic Rezdiffra

Resiliva 80 mg contains the active pharmaceutical ingredient Resmetirom, a first-in-class, liver-directed thyroid hormone receptor-beta (THR-β) agonist. It is explicitly indicated for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH)—recently reclassified as metabolic dysfunction-associated steatohepatitis (MASH)—who have moderate to advanced liver scarring (fibrosis stages F2 to F3). Designed to be used in conjunction with diet and exercise, Resmetirom targets the underlying metabolic dysfunction of the liver, actively reducing lipotoxicity, clearing accumulated hepatic fat, and halting the progression of fibrosis before it advances to irreversible cirrhosis.

Medical Expert Clinical Insight

“For decades, managing patients with NASH has been one of the most frustrating challenges in clinical medicine. When a patient sat in my office with a liver biopsy showing stage 3 fibrosis, the only medical advice I could offer was, ‘You need to lose weight and change your diet.’ While lifestyle modifications are crucial, they are notoriously difficult to sustain, and for many patients, they simply aren’t enough to stop the progression to liver failure.

The approval of targeted THR-β agonists like Resmetirom changed the fundamental reality of hepatology. We finally have a pharmacological tool that goes straight to the source, ‘turning on’ the liver’s natural ability to burn fat and heal scar tissue. However, treating chronic metabolic disease requires years of continuous therapy. When life-saving drugs are priced out of reach, the medical breakthrough is meaningless to the average person. High-quality generic equivalents like Resiliva bridge this critical gap, ensuring that patients can consistently protect their liver health without facing catastrophic financial barriers.“

Clinical Data & Safety Guide

Precise Indications & Diagnostics

• Target Pathology: Noncirrhotic NASH/MASH with F2-F3 fibrosis.
• Diagnostic Requirements: Liver biopsy is the historical gold standard; however, 2026 AASLD guidelines highly support non-invasive testing (NITs) such as FibroScan (VCTE) or MRI-PDFF combined with blood biomarkers (FIB-4) to confirm the degree of steatosis and fibrosis prior to initiation.

Mechanism of Action & Pharmacokinetics

Patients with NASH suffer from impaired hepatic thyroid hormone signaling, leading to fat accumulation and “lipotoxicity.” Resmetirom acts as a highly selective agonist of the THR-β receptor, which is predominantly expressed in the liver. Activation of this receptor normalizes mitochondrial function, accelerates the breakdown of fatty acids (β-oxidation), and reduces systemic triglycerides.

ADME Summary:

• Absorption: Readily absorbed; peak plasma concentration (T_max) is reached in approximately 4 hours.
• Distribution: Highly bound to plasma proteins (>99%).
• Metabolism: Primarily metabolized in the liver by CYP2C8 and UGT1A1/UGT1A3.
• Excretion: Primarily via feces (~67%) and urine (~24%).
• Half-life ($t_{1/2}$): Approximately 4.5 hours.

Dosage & Adverse Event (AE) Management

Baseline Dosing Protocol: Dosing is strictly weight-based.

• < 100 kg (220 lbs): 80 mg orally once daily.
• ≥ 100 kg (220 lbs): 100 mg orally once daily.

Table 1: Grade 1-4 Adverse Event Management Protocol

Clinical Efficacy: The MAESTRO-NASH Trial

The clinical authority of Resmetirom is anchored in the landmark Phase 3 MAESTRO-NASH trial published in The New England Journal of Medicine.

• NASH Resolution: At 52 weeks, 26% to 30% of patients receiving Resmetirom achieved NASH resolution with no worsening of fibrosis, compared to 9.7% of the placebo group.
• Fibrosis Improvement: 24% to 26% of patients achieved an improvement in fibrosis by at least one stage with no worsening of the NAFLD activity score (vs. 14.2% for placebo).
• Real-World Evidence (RWE): Post-marketing data indicates significant secondary benefits, including sustained reductions in atherogenic lipids (LDL-C, apolipoprotein B, and triglycerides), which lowers the overall cardiovascular risk profile—a primary cause of mortality in NASH patients.

Table 2: Pharmacological Interactions & Contraindications

4. Precautions & Special Populations

• Pregnancy & Lactation: There is insufficient data on human pregnancy. However, untreated NASH poses significant maternal/fetal risks. Use only if the clinical benefit justifies the potential risk. Breastfeeding is not recommended due to the potential for serious adverse reactions in the infant.
• Hepatic Impairment: Resmetirom is absolutely contraindicated in patients with decompensated cirrhosis (Child-Pugh Class B or C). The liver’s inability to safely metabolize the drug in this state increases the risk of severe drug-induced liver injury.
• Storage & Logistics: Store at controlled room temperature, 20°C to 25°C (68°F to 77°F). Keep in the original moisture-resistant blister packaging until the time of administration. No cold-chain refrigeration is required.

Manufacturing Quality Assurance and Global Access

Global Access via the Named Patient Program (NPP)

For patients in regions where generic Resmetirom is not locally registered or is financially inaccessible, Resiliva 80 mg can be legally acquired through Personal Use Importation regulations.

Step-by-Step Importation Protocol:

• Valid Medical Prescription: Obtain a formal prescription for Resmetirom 80 mg from a licensed hepatologist or gastroenterologist.
• Letter of Medical Necessity: A brief letter from the treating physician justifying the importation (e.g., local unavailability, high fibrosis risk).
• Medical Review: Our internal pharmacy team reviews the diagnostic staging (F2/F3 confirmation) to ensure the patient is a safe candidate.
• Fulfillment: The medication is shipped via tracked, international medical logistics directly to the patient’s residence or clinic.

Everest Pharmaceuticals Quality Insights

Resiliva is manufactured by Everest Pharmaceuticals, a premier producer of advanced generics. The facility operates under strict WHO-GMP (Good Manufacturing Practices) guidelines. Everest employs high-performance liquid chromatography (HPLC) to ensure the molecular purity of Resmetirom. Every batch undergoes rigorous bioequivalence testing to guarantee the exact pharmacokinetic dissolution and systemic absorption profile as the innovator brand, ensuring uncompromised patient safety.

Table 3: Therapeutic Equivalence Matrix

Frequently Asked Questions (FAQs)